VV-ECMO Study Targets Right Ventricular Injury Before It Becomes Clinically Obvious
Royal Papworth Hospital is preparing a prospective feasibility study that treats the right ventricle as a central organ of concern, not a passive bystander, in patients receiving veno-venous extracorporeal membrane oxygenation for severe acute respiratory failure. The registry, titled Right Heart Injury Monitoring on ECMO, will ask a simple but clinically consequential question: can a standardized surveillance pathway be built into routine VV-ECMO care without overwhelming the bedside team, and without losing sight of patients whose right heart function is deteriorating under the strain of critical illness?
The study is set to enroll 30 adults, with recruitment planned to begin in November 2026 and completion estimated for January 2028. Eligible participants must be at least 18 years old and within 72 hours of being established on VV-ECMO for severe acute respiratory failure, whether they arrive from another hospital or are already admitted at Royal Papworth Hospital. Patients supported for other reasons, including bridge to lung transplantation or post-transplant care, are excluded. The design is prospective and observational, which suits a feasibility question where the first hurdle is operational: can the protocol actually be delivered in a real intensive care setting?
Twice-weekly surveillance is the heart of the protocol. Each patient will undergo a transthoracic echocardiogram with a dedicated right ventricular protocol, along with serial blood testing for high-sensitivity troponin and N-terminal pro-B-type natriuretic peptide. Those measures are intended to track myocardial stress and hemodynamic burden over time, not merely capture a single snapshot. A final heart scan is planned 48 hours after VV-ECMO is discontinued, extending the observation window just long enough to see whether right ventricular abnormalities begin to resolve once extracorporeal support ends.
Why the Right Ventricle Matters During Severe Respiratory Failure
The physiological logic is straightforward. Severe acute respiratory failure increases pulmonary vascular load, and that can strain the right ventricle at precisely the moment when oxygenation is failing and the patient is dependent on advanced organ support. VV-ECMO removes part of the gas-exchange burden from the lungs, but it does not erase the consequences of pulmonary vascular dysfunction, ventilator interactions, inflammatory injury, or the hemodynamic stress that accompanies critical illness. In that setting, right ventricular injury can develop early, persist despite support, or emerge later during the ECMO course.
A single bedside echocardiogram may miss that trajectory. Repeated assessment creates the possibility of identifying early right ventricular injury, late injury, or a phenotype in which the right ventricle can no longer meet flow demand. The study plan explicitly separates patients with and without right ventricular injury, early versus late injury, and mild, moderate, or severe phenotypes. It also asks whether the ventricle is keeping pace with flow demand, a clinically relevant distinction because the same patient may move between compensated and decompensated states over the course of extracorporeal support.
The choice of biomarkers adds another layer of plausibility. Troponin is a marker of myocardial injury, while NT-proBNP reflects wall stress and ventricular loading conditions. Used together with echocardiographic parameters such as pulmonary artery flow acceleration time, RV tissue Doppler isovolumic contraction time, and RV/PA coupling, they may help clinicians spot the onset of deterioration before the bedside picture becomes unmistakable. If a signal appears early enough, it could trigger changes in ventilator strategy, volume management, pulmonary vasodilator use, or the broader ECMO care plan.
This is where feasibility becomes more than a bureaucratic endpoint. A protocol can be scientifically attractive and still fail if the scans are not timed reliably, the biomarkers are not drawn consistently, or the results do not influence decision-making at the bedside. The primary outcome asks whether a multimodal right ventricular monitoring protocol can be implemented in the Royal Papworth critical care environment over a 2-month feasibility window. Secondary outcomes then extend the question to data completeness, evolving biomarker and echo patterns, and whether clinicians actually change management in response to what the protocol reveals.
One sentence captures the clinical tension: right ventricular injury on VV-ECMO may be silent until the hemodynamics fail.
The study also carries a longer observational tail, with certain outcomes tracked over 12 months. Investigators want to know whether regular monitoring can help identify patients who recover from early right ventricular injury after ECMO initiation, those who develop late injury during support, and those who fall into clinically meaningful severity bands. Differences in VV-ECMO duration, ECMO outcome, and critical care area length of stay are also planned endpoints, linking cardiac phenotype to resource use and recovery trajectory.
A Feasibility Registry With Direct Bedside Consequences
The protocol is built around a narrow but important operational question: can intensivists and echocardiographers work from a common surveillance schedule and then use the findings in real time? The registry includes adults with severe acute respiratory failure supported by VV-ECMO, and it aims to recruit consecutive patients with consent. That approach should produce a pragmatic picture of how often the monitoring schedule is achievable in a high-acuity environment where transport, staffing, ventilator adjustments, anticoagulation, and organ support all compete for attention.
The study begins from a literature base that already links right ventricular injury to poor outcomes in ARDS patients on VV-ECMO. Its own cited background includes a 2023 systematic review and meta-analysis showing increased mortality with right ventricular injury, as well as a 2025 report asking whether timing itself matters. The new registry does not try to answer mortality on its own. Instead, it addresses the necessary preliminary step: if clinicians want to act on right ventricular injury, they need a monitoring system that is structured, reproducible, and feasible during the course of ECMO care.
There are also built-in constraints. Enrollment is limited to adults fluent in English, and the target sample is small. The study excludes patients receiving VV-ECMO for reasons other than severe acute respiratory failure, which keeps the cohort clinically coherent but narrows generalizability. It is also an observational registry rather than an interventional trial, so the protocol can describe associations and workflow effects, but it cannot prove that earlier recognition of right ventricular injury improves survival on its own.
Even so, the clinical intent is clear. In severe respiratory failure, right ventricular dysfunction can shape the course of ECMO support, influence management, and alter recovery. A twice-weekly echo-and-biomarker pathway may be enough to move the right ventricle from the periphery of critical care assessment to the center of it. The unanswered issue is not whether the ventricle matters; it does. The question is whether a routine monitoring strategy can capture that injury early enough to change what clinicians do next.